Next Generation Protein Therapeutics & Bioconjugates Summit is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Katherine Harris, PhD
Senior Director of Discovery at TeneoBio Inc.


Katherine Harris is currently Director of Discovery at Teneobio and leads a group focused on antibody discovery. She co-developed a novel sequence-based discovery approach using NGS, bioinformatics and high-throughput recombinant protein expression and screening to identify large collections of sequence-defined and functionally validated antibodies. Her experience also includes development of multi-valent and multi-specific antibody therapeutics. Prior to her work at Teneobio, she was a research scientist at Active Motif and SwitchGear Genomics where she focused her efforts on developing a functional genomics platform for small molecule screening. Dr. Katherine Harris holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

Katherine Harris, PhD's Network

Agenda Sessions

  • PANEL DISCUSSION: Identifying New Targets

    , 11:00am
  • Multi-Specific Antibody Development Using Sequence-Based Antibody Discovery

    , 10:30am

Speakers at this event